Tobacco companies are seeing a resurgence in investor interest, driven by a strategic pivot towards smoke-free products like vapes and nicotine pouches. This shift is leading to improved stock valuations for companies like Philip Morris International and British American Tobacco (BAT), with BAT shares roughly doubling over the past two years, outperforming the "Magnificent Seven" tech stocks.

Regulatory tailwinds are also playing a significant role. The industry anticipates a more favorable environment under a potential second Trump administration compared to the current White House. Furthermore, changes in how the U.S. Food and Drug Administration (FDA) handles premarket tobacco product applications (PMTAs) for new smokeless nicotine products offer a substantial boost. Companies can now sell new products while their PMTA is under review, a change from the previous requirement to wait for approval, which could take years.

This regulatory adjustment is crucial for combating the over two-thirds of U.S. vape products that are currently illicit, many imported from China. By allowing approved products to reach the market faster, companies can capture consumers transitioning from traditional cigarettes and reduce the market share of illegal alternatives. Altria Group, the U.S. maker of Marlboro, has also seen its stock climb more than 50% in the same period.